Prime Medicine (NASDAQ:PRME) Given “Buy” Rating at Chardan Capital

Posted by Brenda Bartman on Sep 25th, 2026

Prime Medicine (NASDAQ:PRME – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $7.00 price objective on the stock. Chardan Capital’s target price would indicate a potential upside of 135.29% from the stock’s previous close.

Other analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Prime Medicine in a report on Monday, August 10th. New Street Research set a $8.00 price target on Prime Medicine in a report on Monday, June 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a report on Monday, August 31st. The Goldman Sachs Group set a $6.00 price target on Prime Medicine in a report on Monday, June 22nd. Finally, BMO Capital Markets started coverage on Prime Medicine in a report on Tuesday, August 18th. They set an “outperform” rating and a $9.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.47.

Read Our Latest Stock Analysis on Prime Medicine

Prime Medicine Stock Down 3.1%

Shares of NASDAQ PRME traded down $0.10 during midday trading on Friday, hitting $2.98. 2,330,381 shares of the company’s stock were exchanged, compared to its average volume of 2,912,694. Prime Medicine has a 12 month low of $2.67 and a 12 month high of $6.94. The company’s 50 day moving average price is $3.25 and its 200 day moving average price is $3.37. The firm has a market capitalization of $539.61 million, a PE ratio of -2.81 and a beta of 2.34.

Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.24) EPS for the quarter, hitting the consensus estimate of ($0.24). Prime Medicine had a negative return on equity of 188.27% and a negative net margin of 4,613.11%.The company had revenue of $1.15 million during the quarter, compared to the consensus estimate of $4.40 million. On average, equities research analysts anticipate that Prime Medicine will post -0.96 EPS for the current year.

Hedge Funds Weigh In On Prime Medicine

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System increased its stake in shares of Prime Medicine by 15.5% in the 2nd quarter. Arizona State Retirement System now owns 28,646 shares of the company’s stock valued at $106,000 after purchasing an additional 3,855 shares during the last quarter. Royal Bank of Canada grew its position in Prime Medicine by 89.3% during the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock worth $32,000 after acquiring an additional 4,365 shares during the last quarter. ProShare Advisors LLC grew its position in Prime Medicine by 37.0% during the 4th quarter. ProShare Advisors LLC now owns 26,158 shares of the company’s stock worth $91,000 after acquiring an additional 7,059 shares during the last quarter. Swiss National Bank grew its position in Prime Medicine by 5.0% during the 1st quarter. Swiss National Bank now owns 178,600 shares of the company’s stock worth $622,000 after acquiring an additional 8,500 shares during the last quarter. Finally, Glen Eagle Advisors LLC bought a new position in Prime Medicine in the fourth quarter valued at about $35,000. 70.37% of the stock is owned by institutional investors and hedge funds.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine, Inc is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations.

Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient.